A5056211996- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Nonmelanoma Skin Cancer Studies
- Colorectal Cancer Treatments and Studies
- Immune cells in cancer
- Advanced Proteomics Techniques and Applications
- Histone Deacetylase Inhibitors Research
- Cancer Research and Treatments
- Synthesis and biological activity
- Brain Metastases and Treatment
- Nanoplatforms for cancer theranostics
- Computational Drug Discovery Methods
- Pharmacological Receptor Mechanisms and Effects
- Phenothiazines and Benzothiazines Synthesis and Activities
- Inflammatory Biomarkers in Disease Prognosis
- Peptidase Inhibition and Analysis
- Advanced Biosensing Techniques and Applications
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
- COVID-19 and healthcare impacts
- Lung Cancer Research Studies
- Quinazolinone synthesis and applications
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2015-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2024
University of Catania
1980
Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated immune checkpoint inhibitors.This was retrospective analysis 97 consecutive stage IV melanoma who were nivolumab. Baseline NLR and derived (d) calculated and, along other characteristics, correlated progression-free survival (PFS) overall (OS) univariate multivariate analyses. The best cutoff values dNLR using...
Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) geriatric patients. These agents associated with immune-related adverse events (irAEs), which may be particularly morbidity this population.To provide insight into outcomes and safety ICIs among cancer.A Multicenter, international retrospective study 928 different tumors treated single-agent between 2010 to 2019 from 18...
Older patients have similar immune checkpoint inhibitor efficacy and rates of adverse events as younger patients, but appear to decreased tolerability, particularly in the oldest patient cohort (>80 years), often leading early cessation therapy. We aimed determine whether discontinuation impacts anti-PD-1 therapy ≥80 years old. In this retrospective, multicenter, international study, we examined 773 with 4 tumor types who were at least 80 old treated determined response rate, overall...
Abstract Treatment duration with checkpoint inhibitors must be optimized to prevent unjustified toxicity, but evidence for the management of cutaneous squamous cell carcinoma is lacking. A retrospective study was performed evaluate survival patients (CSCC) who discontinued cemiplimab due different causes and without progression. Among 95 CSCC received cemiplimab, 22 (23%) immunotherapy other than progression, such as comorbidities, complete response or lack compliance (group that before...
Extensive squamous cell carcinoma has few therapeutic options. In such cases, electrochemotherapy involving electroporation combined with antineoplastic drug appears to be a new potential option and may considered as an alternative treatment. The aim of this retrospective single-center study was evaluate efficacy in treatment locally advanced stage III carcinoma, which surgical procedures would have entailed wide tissue sacrifice. Clinical features, response, adverse effects were evaluated...
It is unknown whether melanoma patients achieving complete response (CR) with targeted therapy can safely discontinue treatment.All treated BRAF/MEK inhibitors CR and ceasing treatment before progression were identified. Clinical data at initiation, cessation examined.A total of 12 eligible identified, median follow-up 16 months, whom 6 (50%) recurred a 6.6 months after cessation. One patient lost to until presentation symptomatic recurrence was the only relapser die. At relapse, remaining...
The optimal sequencing of targeted treatment and immunotherapy in the advanced melanoma is a key question prospective studies to address this are ongoing. Previous observations suggest that treating first with therapy may select for more aggressive disease, meaning patients not gain full benefit from subsequent immunotherapy. In single-center retrospective analysis, we investigated whether response pembrolizumab was affected by previous BRAF inhibitor therapy. A total 42 metastatic cutaneous...
Rationale: Metastatic melanoma is the most aggressive and dangerous form of skin cancer.The introduction immunotherapy with Immune checkpoint Inhibitors (ICI) targeted therapy BRAF MEK inhibitors for mutated melanoma, has greatly improved clinical outcome these patients.Nevertheless, response to remains highly variable development drug resistance continues be a daunting challenge.Within this context there need develop diagnostic tools capable predicting or in order select best therapeutic...
Abstract Background The clinical observation showed a potential additive effect of anti-PD-1 agents and cetirizine in patients with advanced melanoma. Methods Clinical outcomes concomitant cetirizine/anti-PD-1 treatment stage IIIb–IV melanoma were retrospectively collected, transcriptomic analysis was performed on blood samples obtained at baseline after 3 months treatment. Results Patients treated concomitantly an agent had significantly longer progression-free survival (PFS; mean PFS: 28...
Abstract Background Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found affect immune populations which impact tumor development. The aim was investigate the prognostic significance IL-6 serum levels before and during treatment. Methods Serum were correlated with clinical outcomes in a retrospective study. Results Overall, 39 patients enrolled. High (> 5.6 pg/ml) associated poorer survival (45.1% vs...
In recent years the introduction of target therapies with BRAF and MEK inhibitors (MAPKi) immunotherapy anti-CTLA-4 anti-PD-1 monoclonal antibodies have dramatically improved survival metastatic melanoma patients. Despite these changes drug resistance remains a major hurdle. Several mechanisms are at basis resistance. Particular attention has been devoted over last to unravel adaptive/non genetic occurring in mutated melanomas upon treatment MAPKi. this paper we focus on involvement...
Abstract Background Fatigue was reported as the most common any-grade adverse event (18.3%), and grade 3 or higher immune-related (irAE) (0.89%) in patients receiving PD-1/PD-L1 checkpoint inhibitors clinical trial. Methods The aim of this retrospective multicenter study to evaluate correlations between “early ir-fatigue”, “delayed outcomes cancer practice. Results 517 were evaluated. After 12-weeks landmark selection, 386 (74.7%) eligible for analysis. 40.4% NSCLC, 42.2% melanoma, 15.3%...